Application of Chimeric Mice with Humanized Liver for Predictive ADME

REFERENCES

• Bachmann K. A. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr. Drug Metab. 2006; 7: 1–14
   PubMed Web of Science ®Google Scholar
• Caporaso N. E., Shaw G. L. Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine. Arch. Intern. Med. 1991; 151: 1985–1992
   PubMed Web of Science ®Google Scholar
• Corchero J., Granvil C. P., Akiyama T. E., Hayhurst G. P., Pimprale S., Feigenbaum L., Idle J. R., Gonzalez F. J. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol. Pharmacol. 2001; 60: 1260–1267
   PubMed Web of Science ®Google Scholar
• Dandri M., Burda M. R., Torok E., Pollok J. M., Iwanska A., Sommer G., Rogiers X., Rogler C. E., Gupta S., Will H., Greten H., Petersen J. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology. 2001; 33: 981–988
   PubMed Web of Science ®Google Scholar
• Dresser G. K., Spence J. D., Bailey D. G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 2000; 38: 41–57
   PubMed Web of Science ®Google Scholar
• Eichelbaum M., Ingelman-Sundberg M., Evans W. E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 2006; 57: 119–137
   PubMed Web of Science ®Google Scholar
• Gharaibeh M. N., Gillen L. P., Osborne B., Schwartz J. I., Waldman S. A. Effect of multiple doses of rifampicin on the [14C N-methyl] erythromycin breath test in healthy male volunteers. J. Clin. Pharmacol. 1998; 38: 492–495
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon M. J., Donato M. T., Castell J. V., Jover R. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr. Drug. Metab. 2003; 4: 292–312
   PubMed Web of Science ®Google Scholar
• Hemeryck A., Belpaire F. M. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr. Drug Metab. 2002; 3: 13–37
   PubMed Web of Science ®Google Scholar
• Hiroi T., Chow T., Imaoka S., Funae Y. Catalytic specificity of CYP2D isoforms in rat and human. Drug. Metab. Dispos. 2002; 30: 970–976
   PubMed Web of Science ®Google Scholar
• Hutzler M., Messing D. M., Wienkers L. C. Predicting drug-drug interactions in drug discovery: where are we now and where are we going?. Curr. Opin. Drug Discov. Devel. 2005; 8: 51–58
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology. 2002; 181–182: 447–452
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics. J. 2005; 5: 6–13
   PubMed Web of Science ®Google Scholar
• Iwasaki K., Yamato Y., Emoto C., Kuroda M., Soeno Y., Katoh M., Horie T., Yokoi T., Yoshizato K. Induction of cytochrome P450 3A4/5 by rifamycins in chimeric mice with humanized liver. Drug. Metab. Rev. 2005; 37(suppl 2)143
   Google Scholar
• Karim A., Kook C., Zitzewitz D. J., Zagarella J., Doherty M., Campion J. Species differences in the metabolism and disposition of spironolactone. Drug. Metab. Dispos. 1976; 4: 547–555
   PubMed Web of Science ®Google Scholar
• Katoh M., Matsui T., Nakajima M., Tateno C., Kataoka M., Soeno Y., Horie T., Iwasaki K., Yoshizato K., Yokoi T. Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab. Dispos. 2004; 32: 1402–1410
   PubMed Web of Science ®Google Scholar
• Katoh M., Matsui T., Nakajima M., Tateno C., Soeno Y., Horie T., Iwasaki K., Yoshizato K., Yokoi T. In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab. Dispos. 2005a; 33: 754–763
   PubMed Web of Science ®Google Scholar
• Katoh M., Matsui T., Okumura H., Nakajima M., Nishimura M., Naito S., Tateno C., Yoshizato K., Yokoi T. Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab. Dispos. 2005b; 33: 1333–1340
   PubMed Web of Science ®Google Scholar
• Katoh M., Watanabe M., Tabata T., Sato Y., Nakajima M., Nishimura M., Naito S., Tateno C., Iwasaki K., Yoshizato K., Yokoi T. In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver. Xenobiotica. 2005c; 35: 863–875
   PubMed Web of Science ®Google Scholar
• Katoh M., Sawada T., Soeno Y., Nakajima M., Tateno C., Yoshizato K., Yokoi T. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J. Pharm. Sci. 2007, in press
   Web of Science ®Google Scholar
• Ko H., Novak E., Peters G. R., Bothwell W. M., Hosley J. D., Closson S. K., Adams W. J. Pharmacokinetics of single-dose cefmetazole following intramuscular administration of cefmetazole sodium to healthy male volunteers. Antimicrob. Agents Chemother. 1989; 33: 508–512
   PubMed Web of Science ®Google Scholar
• Kolis S. J., Williams T. H., Schwartz M. A. Identification of the urinary metabolites of 14C-bumetanide in the rat and their excretion by rats and dogs. Drug Metab. Dispos. 1976; 4: 169–176
   PubMed Web of Science ®Google Scholar
• Li A. P., Maurel P., Gomez-Lechon M. J., Cheng L. C., Jurima-Romet M. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem. Biol. Interact. 1997a; 107: 5–16
   PubMed Web of Science ®Google Scholar
• Li A. P., Reith M. K., Rasmussen A., Gorski J. C., Hall S. D., Xu L., Kaminski D. L., Cheng L. K. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem. Biol. Interact. 1997b; 107: 17–30
   PubMed Web of Science ®Google Scholar
• Lin J. H., Lu A. Y. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu. Rev. Pharmacol. Toxicol. 2001; 41: 535–567
   PubMed Web of Science ®Google Scholar
• Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet. 1977; 2: 584–586
   PubMed Web of Science ®Google Scholar
• Masubuchi Y., Iwasa T., Hosokawa S., Suzuki T., Horie T., Imaoka S., Funae Y., Narimatsu S. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes. J. Pharmacol. Exp. Ther. 1997; 282: 1435–1441
   PubMed Web of Science ®Google Scholar
• Mercer D. F., Schiller D. E., Elliott J. F., Douglas D. N., Hao C., Rinfret A., Addison W. R., Fischer K. P., Churchill T. A., Lakey J. R., Tyrrell D. L., Kneteman N. M. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 2001; 7: 927–933
   PubMed Web of Science ®Google Scholar
• Miners J. O., McKinnon R.A., Mackenzie P. I. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology. 2002; 181–182: 453–456
   PubMed Web of Science ®Google Scholar
• Murakawa T., Sakamoto H., Fukada S., Nakamoto S., Hirose T., Itoh N., Nishida M. Pharmacokinetics of ceftizoxime in animals after parenteral dosing. Antimicrob. Agents Chemother. 1980; 17: 157–164
   PubMed Web of Science ®Google Scholar
• Nagar S., Remmel R. P. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene. 2006; 25: 1659–1672
   PubMed Web of Science ®Google Scholar
• Nakajima M., Tane K., Nakamura S., Shimada N., Yamazaki H., Yokoi T. Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b5 in the expression system and the differences in the marker activities. J. Pharm. Sci. 2002; 91: 952–963
   PubMed Web of Science ®Google Scholar
• Nelson D. R., Koymans L., Kamataki T., Stegeman J. J., Feyereisen R., Waxman D. J., Waterman M. R., Gotoh O., Coon M. J., Estabrook R. W., Gunsalus I. C., Nebert D. W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996; 6: 1–42
   PubMedGoogle Scholar
• Niemi M., Backman J. T., Fromm M. F., Neuvonen P. J., Kivisto K. T. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 2003; 42: 819–850
   PubMed Web of Science ®Google Scholar
• Nishimura M., Yokoi T., Tateno C., Kataoka M., Takahashi E., Horie T., Yoshizato K., Naito S. Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. Drug Metab. Pharmacokinet. 2005a; 20: 121–126
   PubMedGoogle Scholar
• Nishimura M., Yoshitsugu H., Yokoi T., Tateno C., Kataoka M., Horie T., Yoshizato K., Naito S. Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica. 2005b; 35: 877–890
   PubMed Web of Science ®Google Scholar
• Pascussi J. M., Gerbal-Chaloin S., Daujat M., Drocourt L., Pichard-Garcia L., Vilarem M. J., Maurel P., Klieber S., Torreilles F., Bourrie M., Guillou F., Fabre G. CYP gene induction by xenobiotics and drugs. Drug Metabolizing Enzymes, J. S. Lee, R. S. Obach, M B. Fisher. Marcel Dekker, New York 2003; 337–374
   Google Scholar
• Perucca E., Grimaldi R., Frigo G. M., Sardi A., Mönig H., Ohnhaus E. E. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur. J. Clin. Pharmacol. 1988; 34: 595–599
   PubMed Web of Science ®Google Scholar
• Robertson G. R., Field J., Goodwin B., Bierach S., Tran M., Lehnert A., Liddle C. Transgenic mouse models of human CYP3A4 gene regulation. Mol. Pharmacol. 2003; 64: 42–50
   PubMed Web of Science ®Google Scholar
• Rodrigues A. D., Rushmore T. H. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr. Drug Metab. 2002; 3: 289–309
   PubMed Web of Science ®Google Scholar
• Ronis M. J. J., Ingelman-Sundberg M. Induction of human drug metabolizing enzymes: mechanisms and implications. Handbook of Drug Metabolism, T. F. Woolf. Marcel Dekker, New York 1999; 239–262
   Google Scholar
• Tateno C., Yoshizane Y., Saito N., Kataoka M., Utoh R., Yamasaki C., Tachibana A., Soeno Y., Asahina K., Hino H., Asahara T., Yokoi T., Furukawa T., Yoshizato K. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 2004; 165: 901–912
   PubMed Web of Science ®Google Scholar
• Tomlinson E. S., Maggs J. L., Park B. K., Back D. J. Dexamethasone metabolism in vitro: species differences. J. Steroid. Biochem. Mol. Biol. 1997; 62: 345–352
   PubMed Web of Science ®Google Scholar
• Zhang W., Purchio A. F., Chen K., Wu J., Lu L., Coffee R., Contag P. R., West D. B. A transgenic mouse model with a luciferase reporter for studying in vivo transcriptional regulation of the human CYP3A4 gene. Drug Metab. Dispos. 2003; 31: 1054–1064
   PubMed Web of Science ®Google Scholar
• Zhou S., Chan S. Y., Goh B. C., Chan E., Duan W., Huang M., McLeod H. L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 2005; 44: 279–304
   PubMed Web of Science ®Google Scholar